Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged ≥65 Years — COVID-NET, 13 States, February–April 2021

Details

• Journal Article:
  Morbidity and Mortality Weekly Report (MMWR)
• Personal Author:
  Moline, Heidi L. ; Whitaker, Michael ; Deng, Li ; Rhodes, Julia C. ; Milucky, Jennifer ; Pham, Huong ; Patel, Kadam ; Anglin, Onika ; Reingold, Arthur ; Chai, Shua J. ; Alden, Nisha B. ; Kawasaki, Breanna ; Meek, James ; Yousey-Hindes, Kimberly ; Anderson, Evan J. ; Farley, Monica M. ; Ryan, Patricia A. ; Kim, Sue ; Nunez, Val Tellez ; Como-Sabetti, Kathryn ; Lynfield, Ruth ; Sosin, Daniel M. ; McMullen, Chelsea ; Muse, Alison ; Barney, Grant ; Bennett, Nancy M. ; Bushey, Sophrena ; Shiltz, Jessica ; Sutton, Melissa ; Abdullah, Nasreen ; Talbot, H. Keipp ; Schaffner, William ; Chatelain, Ryan ; Ortega, Jake ; Murthy, Bhavini Patel ; Zell, Elizabeth ; Schrag, Stephanie J. ; Taylor, Christopher ; Shang, Nong ; Verani, Jennifer R. ; Havers, Fiona P.
• Description:
  Clinical trials of COVID-19 vaccines currently authorized for emergency use in the United States (Pfizer-BioNTech, Moderna, and Janssen [Johnson & Johnson]) indicate that these vaccines have high efficacy against symptomatic disease, including moderate to severe illness (1-3). In addition to clinical trials, real-world assessments of COVID-19 vaccine effectiveness are critical in guiding vaccine policy and building vaccine confidence, particularly among populations at higher risk for more severe illness from COVID-19, including older adults. To determine the real-world effectiveness of the three currently authorized COVID-19 vaccines among persons aged ≥65 years during February 1-April 30, 2021, data on 7,280 patients from the COVID-19-Associated Hospitalization Surveillance Network (COVID-NET) were analyzed with vaccination coverage data from state immunization information systems (IISs) for the COVID-NET catchment area (approximately 4.8 million persons). Among adults aged 65-74 years, effectiveness of full vaccination in preventing COVID-19-associated hospitalization was 96% (95% confidence interval [CI] = 94%-98%) for Pfizer-BioNTech, 96% (95% CI = 95%-98%) for Moderna, and 84% (95% CI = 64%-93%) for Janssen vaccine products. Effectiveness of full vaccination in preventing COVID-19-associated hospitalization among adults aged ≥75 years was 91% (95% CI = 87%-94%) for Pfizer-BioNTech, 96% (95% CI = 93%-98%) for Moderna, and 85% (95% CI = 72%-92%) for Janssen vaccine products. COVID-19 vaccines currently authorized in the United States are highly effective in preventing COVID-19-associated hospitalizations in older adults. In light of real-world data demonstrating high effectiveness of COVID-19 vaccines among older adults, efforts to increase vaccination coverage in this age group are critical to reducing the risk for COVID-19-related hospitalization.
• Subjects:
  Aged CoronaVirus Infections COVID-19 COVID-19 Vaccines Hospitalization Humans Vaccines, Synthetic
• Source:
  MMWR Morbidity Mortal Weekly Rep. 70(32):1088-1093
• Series:
  Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
• DOI:
  http://dx.doi.org/10.15585/mmwr.mm7032e3
• ISSN:
  0149-2195 (print) ; 1545-861X (digital)
• Pubmed ID:
  34383730
• Pubmed Central ID:
  PMC8360274
• Document Type:
  Journal Article
• Place as Subject:
  United States
• Pages in Document:
  6 pdf pages
• Volume:
  70
• Issue:
  32
• Collection(s):
  Morbidity and Mortality Weekly Report (MMWR)
• Main Document Checksum:
  urn:sha-512:fea980de520060082f3167d2f1e2be323e2f74c00f8ad432b8ed3dda90fdf93047b3eeef8c7c486b7a196fbe17a08ceb3ad85810f5525a702b878db882fecdf6
• Download URL:
  https://stacks.cdc.gov/view/cdc/109808/cdc_109808_DS1.pdf
• File Type:
  [PDF - 175.81 KB ]